| Trial results
Lilly says that in exit interviews from a phase 2 trial of eloralintide, 74% of participants treated with the medicine reported fewer food cravings at 48 weeks, especially for sugary foods, and 52% reported less food noise. Among people who drank alcohol at the start, 41% reported drinking less. The figures are shares of people who said so. They are not sizes of reduction. Lilly gave no number of people interviewed and no placebo comparison, so these are early, company-reported, self-reported findings.
What was reported
| Question | What Lilly's release says |
|---|---|
| Fewer food cravings | 74% of participants treated with eloralintide reported fewer cravings at 48 weeks, especially for sugary foods |
| Less food noise | 52% reported less food noise |
| Drinking less alcohol | Among those who drank alcohol at baseline, 41% reported drinking less |
| How many people were interviewed | Not stated |
| Which eloralintide doses | Not stated |
| A placebo comparison | Not stated |
| How food noise was defined and asked about | Not stated |
| How alcohol use was measured | Not stated |
| Side effects | Not part of this report |
Company-reported, from Lilly's release of November 14, 2026. The data are listed as an eloralintide poster at ObesityWeek 2026 in Washington, D.C.
What "food noise" means
Food noise is a popular term, not a medical diagnosis. People use it for constant thoughts about food and eating that are hard to switch off. There is no single agreed way to measure it, so the way a trial asks about it can change the answer. Lilly's release does not say how it asked.
Why the missing details matter
A percentage of people means little without the number of people behind it. The release does not say whether 74% refers to everyone treated with eloralintide in the trial or to those who took part in an interview, and it does not say how the doses were split. It also gives no placebo group. People who get a placebo in a trial can report changes in appetite too, so the comparison matters before anyone concludes the medicine caused the change.
Weight loss can also reduce cravings by itself. In the phase 2 trial, people on eloralintide lost an average of 9% to 20% of body weight at 48 weeks, depending on dose, and the release does not separate an effect on appetite from an effect of losing weight. See the eloralintide page for the phase 2 results.
Lilly says only "Phase 2" and "48 weeks." It does not name the trial. The Atlas assumes this is the 48-week phase 2 obesity trial it covers on the medicine page, but the release does not confirm that.
What this does and does not tell you
Amylin is linked to fullness after meals, and the interviews add a patient-experience angle to the weight-loss numbers. They do not show that eloralintide reduces alcohol use, and the alcohol finding comes from an unspecified group of people who already drank. Eloralintide is not approved anywhere, and phase 3 trials are under way.
Worth knowing: These are company-reported, self-reported results from an unnamed phase 2 trial, with no group size and no placebo comparison. They come from a press release about a poster, and the Atlas has not seen the poster. This page is general information, not medical advice.
Related: Eloralintide medicine page | Lilly tracker
Source: Lilly press release, November 14, 2026 Company announcement, not peer reviewed.